{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:57:14Z","timestamp":1781697434197,"version":"3.54.5"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":167,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Belimumab has well-established efficacy in improving overall SLE disease activity and preventing flares and organ damage. Belimumab effects have been demonstrated across organ domains but have not been reported in detail for haematological manifestations. We investigated the efficacy of belimumab in thrombocytopenia and leucopenia in patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Anonymised data on haematological parameters from five phase III randomised controlled clinical trials of belimumab were provided by GSK. These datasets included 1769 patients treated with belimumab and 1144 patients who received placebo, on top of standard therapy. We selected patients with active thrombocytopenia or leucopenia at baseline and compared sustained resolution of symptoms from the time of resolution through week 52 by means of log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, thrombocytopenia and leucopenia were present in 39 and 346 belimumab-treated patients and 25 and 203 placebo recipients, respectively. Thrombocytopenia resolved earlier with belimumab versus placebo, starting from week 2 on therapy and in a higher proportion of belimumab-treated patients (p=0.0267). One-third (13\/39) of belimumab-treated and 8% (2\/25) of placebo-receiving patients reached persistent resolution. In contrast to thrombocytopenia, observed improvements in leucopenia were slower, with no apparent difference between belimumab and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This post hoc analysis of data from five large phase III RCTs suggests a benefit from belimumab compared with placebo in the haematological domain. A benefit from belimumab was seen in improving thrombocytopenia, but not leucopenia. While mild leucopenia is rarely clinically relevant, the data on thrombocytopenia will inform differential therapeutic decisions in patients with active SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-002010","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:30:22Z","timestamp":1781695822000},"page":"e002010","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Belimumab induces early and sustained resolution of lupus thrombocytopenia"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-5259","authenticated-orcid":false,"given":"Nicolai","family":"Leuchten","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, and University Center for Autoimmune and Rheumatic Entities (UCARE), University Medical Center and Faculty of Medicine, TUD Dresden University of Technology, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-6592","authenticated-orcid":false,"given":"Ralph","family":"Brinks","sequence":"additional","affiliation":[{"name":"Department for Medical Biometry and Epidemiology, Faculty of Health, University of Witten\/Herdecke, Witten, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, and University Center for Autoimmune and Rheumatic Entities (UCARE), University Medical Center and Faculty of Medicine, TUD Dresden University of Technology, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2026061704300672000_13.1.e002010.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223741"},{"key":"2026061704300672000_13.1.e002010.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01898-7"},{"key":"2026061704300672000_13.1.e002010.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"2026061704300672000_13.1.e002010.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920"},{"key":"2026061704300672000_13.1.e002010.5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00578-x"},{"key":"2026061704300672000_13.1.e002010.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219373"},{"key":"2026061704300672000_13.1.e002010.7","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026061704300672000_13.1.e002010.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2026061704300672000_13.1.e002010.9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026061704300672000_13.1.e002010.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026061704300672000_13.1.e002010.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026061704300672000_13.1.e002010.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.24698"},{"key":"2026061704300672000_13.1.e002010.13","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"JRheumatol"},{"key":"2026061704300672000_13.1.e002010.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"key":"2026061704300672000_13.1.e002010.15","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026061704300672000_13.1.e002010.16","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/art.39682","article-title":"Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials","volume":"68","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026061704300672000_13.1.e002010.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121368"},{"key":"2026061704300672000_13.1.e002010.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831"},{"key":"2026061704300672000_13.1.e002010.19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ard.2025.08.016","article-title":"Belimumab induces early and sustained resolution of lupus arthritis","volume":"85","author":"Leuchten","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026061704300672000_13.1.e002010.20","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/rheumatology\/keaf145","article-title":"Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials","volume":"64","author":"Grosso","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026061704300672000_13.1.e002010.21","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026061704300672000_13.1.e002010.22","doi-asserted-by":"crossref","unstructured":"Sammaritano LR , Askanase A , Bermas BL , et al . 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Rheumatol 2025. doi:10.1002\/art.43452","DOI":"10.1002\/art.43452"},{"key":"2026061704300672000_13.1.e002010.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026061704300672000_13.1.e002010.24","unstructured":"Navarra S , Ilianova E , Bae SC , et al . Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis 2010;69."},{"key":"2026061704300672000_13.1.e002010.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2026061704300672000_13.1.e002010.26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026061704300672000_13.1.e002010.27","article-title":"Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus","volume":"35","author":"De Marchi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026061704300672000_13.1.e002010.28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/mrcr\/rxad055","article-title":"Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases","volume":"8","author":"Nakayama","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2026061704300672000_13.1.e002010.29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/03009742.2023.2247881","article-title":"Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies","volume":"53","author":"Dong","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"2026061704300672000_13.1.e002010.30","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/09612033241241576","article-title":"The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study","volume":"33","author":"Wu","year":"2024","journal-title":"Lupus"},{"key":"2026061704300672000_13.1.e002010.31","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/acr.24078","article-title":"Associations Between Classification Criteria Items in Systemic Lupus Erythematosus","volume":"72","author":"Touma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026061704300672000_13.1.e002010.32","doi-asserted-by":"crossref","first-page":"103721","DOI":"10.1016\/j.autrev.2024.103721","article-title":"Risk factors associated with thrombocytopenia in systemic lupus erythematosus: A systematic review and meta-analysis","volume":"24","author":"Yang","year":"2025","journal-title":"Autoimmun Rev"},{"key":"2026061704300672000_13.1.e002010.33","doi-asserted-by":"crossref","first-page":"102887","DOI":"10.1016\/j.jaut.2022.102887","article-title":"Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment","volume":"132","author":"Jiang","year":"2022","journal-title":"J Autoimmun"},{"key":"2026061704300672000_13.1.e002010.34","doi-asserted-by":"crossref","first-page":"102395","DOI":"10.1016\/j.autrev.2019.102395","article-title":"Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"18","author":"Chock","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026061704300672000_13.1.e002010.35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10067-024-07235-5","article-title":"Immune thrombocytopenia in patients with systemic lupus erythematosus","volume":"44","author":"Zheng","year":"2025","journal-title":"Clin Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:30:27Z","timestamp":1781695827000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,17]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2026-002010"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002010","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}